news
Protease inhibitor aprotinin shows promise against SARS-CoV-2 in cells
Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.
List view / Grid view
Covid-19
news
Persistence of infected cells in lungs could explain long-term COVID-19 symptoms, say scientists
Researchers have found the genome of COVID-19 and infected cell syncytia in the respiratory cells of deceased patients, potentially explaining long-term coronavirus effects.
news
Autoantibodies and over-active neutrophils may be cause of COVID-19 blood clots
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
news
SARS-CoV-2 can disrupt the blood-brain barrier, find scientists
Binding of SARS-CoV-2 spike proteins to the brain’s endothelial cells can cause the blood-brain barrier to become leaky, potentially causing the neurological symptoms associated with COVID-19.
news
SARS-CoV-2 specific antibodies persist for five months in mild cases
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
news
Lysosomes key to coronavirus shedding, finds study
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
news
Leveraging flow cytometry to explore COVID-19 immune responses
Researchers used flow cytometry to characterise which types of T cells are involved in the immune response to COVID-19 and what they target.
news
New imaging method reveals glycan vaccine targets on HIV molecules
Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
news
Flow cytometry market to exhibit CAGR of 12 percent
A new report has said that by 2023, the flow cytometry market will be worth $8.88 billion, partly due to an increase in stem cell research.
news
Mini lung organoids reveal early SARS-CoV-2 infection process
Using lung organoids, researchers have shown that 48 hours after SARS-CoV-2 infection, the innate immune response began.
article
Treating cytokine storms in COVID-19 patients
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
![A coiling protein 'shell,' called a nucleocapsid, shown here, surrounds Ebola's genetic material, which consists of single-strand RNA. University of Delaware researchers are simulating the way molecules of this nucleocapsid move and interact, atom by atom, to understand their functions and expose targets for anti-viral treatments [Credit: Juan Perilla Laboratory].](https://www.drugtargetreview.com/wp-content/uploads/Ebola-nucleocapsid-e1603365997854.jpg)
news
The nucleocapsid as a novel drug target for Ebola virus
Using supercomputer stimulations researchers reveal that the structural stability of the Ebola nucleocapsid is depended on the presence of RNA and interactions with charged ions.
news
Severe COVID-19 symptoms may not be caused by cytokine storm
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
news
SARS-CoV-2 also uses neuropilin-1 to infect human cells
Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.
news
CBD could treat inflammation caused by COVID-19, study shows
Researchers have found that CBD reduces inflammation in the lungs of COVID-19 mouse models by increasing levels of the apelin peptide.